A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma

Trial Profile

A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2017

At a glance

  • Drugs Rose bengal sodium (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Provectus Biopharmaceuticals
  • Most Recent Events

    • 11 Oct 2016 Trial design of this and other study (PV-10-MM-31and PV-10-MM-1201) presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Trial protocol presented at the European Society of Medical Oncology 2016 Congress, according to a Provectus Biopharmaceuticals media release.
    • 09 Jun 2016 Results presented at the Annual Meeting of the American Society of Clinical Oncology, as per Provectus Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top